A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Launched by AC IMMUNE SA · Jul 13, 2022

Keywords

ClinConnect Summary

The ABATE Study is a clinical trial that is looking at a new treatment called ACI-24.060 to see how safe it is and how well it works for people with early-stage Alzheimer's disease and adults with Down syndrome who do not have dementia. The study aims to find out if this treatment can help manage symptoms and improve brain health in these groups. Researchers are currently recruiting participants who are between 35 and 85 years old, with specific diagnoses related to Alzheimer's disease or Down syndrome, and who meet certain health criteria.

If you or a loved one are eligible to participate, you can expect to undergo some tests, including brain scans, to determine your condition. Participants will receive the treatment and will be monitored closely by the study team to check for any side effects and to see how the treatment is affecting their condition. It’s important to note that there are some health issues that could prevent participation, such as certain medical conditions or recent treatments. Overall, this study hopes to contribute to better understanding and treatment options for Alzheimer's disease and Down syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Study Part 1
• • 1. Age ≥50 and ≤85 years at screening.
• • 2. Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging Alzheimer's Association (NIA-AA) criteria.
• • 3. PET scan at screening consistent with the presence of amyloid pathology.
• • 4. Clinical Dementia Rating (CDR)-Global Score of 0.5.
• • 5. Subjects either not taking any marketed treatment for AD or receiving a stable dose of an acetylcholinesterase inhibitor (ACHEI) and/or memantine for at least 2 months prior to baseline.
• • Study Part 2
• • 1. Age ≥35 and ≤50 years at screening (subjects with DS with age ≥35 and ≤39 years may be considered on the condition that there is prior evidence of amyloid results compatible with AD pathology at PET-scan and/or in biofluids).
• • 2. Male or female subjects with DS with a cytogenetic diagnosis being either trisomy 21 or complete unbalanced translocation of the chromosome 21.
• • 3. PET scan at screening consistent with the presence of amyloid pathology.
• • 4. Mild to moderate intellectual disability as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classification.
• • 5. Subjects must have a study partner who has direct and regular contact, at least 10 hours per week, with the subject and who is able to provide reliable answers to questions related to the subject, according to the study investigator.
• Exclusion Criteria:
• • 1. Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of the study vaccine (eg, moderate and/or severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.
• • 2. DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
• • 3. History or presence of uncontrolled seizures. If history of seizures, they must be well controlled with no occurrence of seizures in the 2 years before study screening. The use of antiepileptic medications is permitted.
• • 4. Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks \[TIAs\], hemorrhagic and/or non-hemorrhagic stroke).
• • 5. History of meningitis or meningoencephalitis.
• • 6. History of moderate or severe traumatic brain injury.
• • 7. History of inflammatory neurological disorders.
• • 8. History or presence of immunological or inflammatory conditions, including neurological disorders, judged to be clinically significant by the investigator.
• • 9. History of severe allergic reaction (eg, anaphylaxis) including, but not limited to severe allergic reaction to previous vaccines, foods, and/or medications.
• • 10. Significant risk of suicide, defined using the C-SSRS as the subject answering "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior within the past 12 months.
• • 11. MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or evidence of a previous macro-hemorrhage or showing more than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"). Evidence of space occupying lesions other than benign meningioma of less than 1 cm diameter, more than 2 lacunar infarcts, or 1 single infarct larger than 1 cm in diameter. Screening MRI scan showing structural evidence of alternative pathology not consistent with AD and is considered to be at the origin of subject's symptoms.
• • 12. Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.
• • 13. Subjects with a positive Human Immunodeficiency Virus (HIV-1 and 2) test at screening.
• • 14. Subjects with clinical or laboratory evidence of active hepatitis B or C at screening (eg, HBV or HCV antigens).
• • 15. Subjects with positive syphilis serology consistent with active syphilis at screening.
• • 16. MRI examination cannot be done for any reason, including but not limited to metal implants contraindicated for MRI and/or severe claustrophobia.
• • 17. Any contraindication for PET scan imaging.
• • 18. Any contraindication to lumbar puncture in subjects undergoing this procedure (note: lumbar puncture is optional in subjects with DS).
• • 19. Previous treatment with ACI-24 or any other active immunotherapy against AD at any time in the past unless there is firm evidence that the subject received placebo only and the placebo formulation is not expected to induce any specific immune response.
• • 20. Previous treatment with any investigational and/or marketed passive immunotherapy against AD within 6 months before screening or 5 half-lives, whichever is longer, unless there is firm evidence that the subject received placebo only.
• • 21. Ongoing treatment with any approved anti-amyloid passive immunotherapy for Alzheimer's disease.
• • 22. Use of acetylcholinesterase inhibitor or glutamatergic drugs (eg, memantine, topiramate, lamotrigine) if not on stable dose for at least 2 months before screening.
• • 23. Any vaccine received within the 2 weeks before screening, including an anti-influenza or anti-COVID 19 vaccine received within 4 weeks before randomization.
• • 24. Subjects with treated hypothyroidism not on a stable dose of replacement medication for at least 2 months before screening and having clinically significant abnormal serum T4 and/or thyroid stimulating hormone at screening.
• • 25. Subjects undergoing lumbar puncture and being treated with any anticoagulants or antiplatelet drugs, except aspirin at doses of 100 mg daily or lower.
• • 26. Use of antidepressants (other than selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors at stable dose); typical antipsychotics; γ-aminobutyric acid agonists (eg, gabapentin); or stimulants (eg, methylphenidate, modafinil). Stable doses of atypical antipsychotics or benzodiazepines are only allowed if this is not considered to influence the safety and the efficacy of the study vaccine according to the site investigator and the sponsor medical monitor.
• • 27. Chronic use of opioid analgesics. A limited treatment duration for acute conditions until 24 hours before cognitive assessment is allowed.
• • 28. Current use of immunosuppressant or immunomodulating drugs or their use within the 6 months before study screening. Current use of oral steroids or their use within the 3 months before study screening.
• • Additional Exclusion Criteria in Study Part 2
• The following are exclusion criteria at the time of randomization but will not be considered as exclusionary after treatment assignment:
• • 29. Clinical diagnosis of AD dementia in DS as per International Classification of Diseases 10 (ICD-10).
• • 30. DSQIID \>20.
• • 31. Intelligence quotient score \<40 (KBIT-2).